Compounds > 4-hydroxypenbutolol
Page last updated: 2024-11-07

4-hydroxypenbutolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-hydroxypenbutolol: penbutolol metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133713
MeSH IDM0105726

Synonyms (15)

Synonym
msv4q3g0oa ,
unii-msv4q3g0oa
phenol, 3-cyclopentyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-, (s)-
ccris 1112
4-hydroxypenbutolol
81542-82-7
4-[(2s)-3-(tert-butylamino)-2-hydroxypropoxy]-3-cyclopentylphenol
3-cyclopentyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenol, (s)-
4'-hydroxypenbutolol
phenol, 3-cyclopentyl-4-((2s)-3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-
AS-6179
Q27284217
4-[3-(tert-butylamino)-2-hydroxypropoxy]-3-cyclopentylphenol
DTXSID701002042
AKOS037645616

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"84 h and then declined bi-exponentially, with an apparent elimination half-life of 21."( Pharmacokinetics of penbutolol and its metabolites in renal insufficiency.
Bernard, N; Cuisinaud, G; Pozet, N; Sassard, J; Zech, PY, 1985)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		1.9610aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
penbutolol
Penbutolol: A nonselective beta-blocker used as an antihypertensive and an antianginal agent.		8.3570ethanolamines
ConditionIndicatedRelationship StrengthStudiesTrials
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		02.3720
Blood Pressure, High
[description not available]		01.9610
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		01.9610